Diagnostic and prognostic value of plasma and tissue ubiquitin-like, containing PHD and RING finger domains 1 in breast cancer patients

Cancer Science

Volumn 104, Issue 2, 2013, Pages 194-199

  Geng, Yao ^a   Gao, Yanfang ^b   Ju, Huangxian ^a   Yan, Feng ^b  

^a NANJING UNIVERSITY   (China)

^b JIANGSU CANCER HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; EPIDERMAL GROWTH FACTOR RECEPTOR 2; TUMOR MARKER; UBIQUITIN LIKE CONTAINING PHD AND RING FINGER DOMAINS 1; UNCLASSIFIED DRUG;

ARTICLE; BLOOD LEVEL; BREAST CANCER; CANCER STAGING; CANCER SURVIVAL; CANCER TISSUE; CONTROLLED STUDY; CORRELATIONAL STUDY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; TISSUE LEVEL; WESTERN BLOTTING;

BREAST NEOPLASMS; CASE-CONTROL STUDIES; CCAAT-ENHANCER-BINDING PROTEINS; CELL LINE, TUMOR; DISEASE-FREE SURVIVAL; DNA, NEOPLASM; FEMALE; FOLLOW-UP STUDIES; GENES, ERBB-2; HUMANS; LYMPHATIC METASTASIS; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; RNA, MESSENGER;

EID: 84873717514     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/cas.12052     Document Type: Article

References (33)

1. Xu GW, Hu YS, Kan X. The preliminary report of breast cancer screening for 100000 women in China. China Cancer 2010; 19: 565-8.
2. Weigelt B, Peterse JL, van't Veer LJ. Breast cancer metastasis: marker and models. Nat Rev Cancer 2005; 5: 591-602.
3. van't Veer LJ, Dai H, van de Vijver MJ et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002; 415: 530-6.
4. van de Vijver MJ, He YD, van't Veer LJ et al. A gene-expression signature as a predictor of survival in breast cancer. N Eng J Med 2002;347:1999-2009.
5. Kim JK, Esteve PO, Jacobsen SE, Pradhan S. UHRF1 binds G9a and participates in p21transcriptional regulation in mammalian cells. Nucleic Acids Res 2009; 37: 493-505.
6. Bostick M, Kim JK, Estève PO, Clark A, Pradhan S, Jacobsen SE. UHRF1 plays a role in maintaining DNA methylation in mammalian cells. Science 2007; 317: 1760-4.
7. Unoki M, Daigo Y, Koinuma J, Tsuchiya E, Hamamoto R, Nakamura Y. UHRF1 is a novel diagnostic marker of lung cancer. Br J Cancer 2010; 103: 217-22.
8. Jin W, Chen L, Chen Y et al. UHRF1 is associated with epigenetic silencing of BRCA1 in sporadic breast cancer. Breast Cancer Res Treat 2010; 123: 359-73.
9. Unoki M, Kelly JD, Neal DE, Ponder BA, Nakamura Y, Hamamoto R. UHRF1 is a novel molecular marker for diagnosis and the prognosis of bladder cancer. Br J Cancer 2009; 101: 98-105.
10. Jin W, Liu Y, Xu SG et al. UHRF1 inhibits MDR1 gene transcription and sensitizes breast cancer cells to anticancer drugs. Breast Cancer Res Treat 2010; 124: 39-48.
11. Gal S, Fidler C, Lo YM et al. Quantitation of circulating DNA in the serum of breast cancer patients by real-time PCR. Br J Cancer 2004; 90: 1211-5.
12. Chang HW, Lee SA, Goodman SN et al. Assessment of plasma DNA levels, allelic imbalance, and CA 125 as diagnostic tests for cancer. J Natl Cancer Inst 2002; 94: 1697-703.
13. Hohaus S, Giachelia M, Massini G et al. Cell-free circulating DNA in Hodgkin's and non-Hodgkin's lymphomas. Ann Oncol 2009; 20: 1408-13.
14. Ren J, Li W, Yan L et al. Expression of CIP2A in renal cell carcinomas correlates with tumour invasion, metastasis and patients' survival. Br J Cancer 2011; 105: 1905-11.
15. Gibson UE, Heid CA, Williams PM. A novel method for real time quantitative RT-PCR. Genome Res 1996; 6: 995-1001.
16. Hanley JA, McNeil BJ. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 1982; 143: 29-36.
17. Daskalos A, Oleksiewicz U, Filia A et al. UHRF1-mediated cancer suppressor gene inactivation in nonsmall cell lung cancer. Cancer 2011; 117: 1027-37.
18. Hashimoto H, Horton JR, Zhang X, Cheng X. UHRF1: a modular multi-domain protein, regulates replication-coupled crosstalk between DNA methylation and histone modifications. Epigenetics 2009; 4: 8-14.
19. Schaefer CB, Ooi SK, Bestor TH, Bourc'his D. Epigenetic decisions in mammalian germ cells. Science 2007; 316: 398-9.
20. Henderson IR, Jacobsen SE. Epigenetic inheritance in plants. Nature 2007; 447: 418-24.
21. Jenkins Y, Markovtsov V, Lang W et al. Critical role of the ubiquitin ligase activity of UHRF1, a nuclear ring finger protein, in cancer cell growth. Mol Biol Cell 2005; 16: 5621-9.
22. Chen X, Bonnefoi H, Diebold-Berger S et al. Detecting cancer-related alterations in plasma or serum DNA of patients diagnosed with breast cancer. Clin Cancer Res 1999; 5: 2297-303.
23. Leung TN, Zhang J, Lau TK, Chan LY, Lo YM. Increased maternal plasma fetal DNA concentrations in women who eventually develop preeclampsia. Clin Chem 2001; 47: 137-9.
24. Sozzi G, Conte D, Mariani L et al. Analysis of circulating tumor DNA at diagnosis and during follow-up of lung cancer patients. Cancer Res 2001; 61: 4675-8.
25. Lo YM, Tein MS, Lau TK et al. Quantitative analysis of fetal DNA in maternal plasma and serum: implications for noninvasive prenatal diagnosis. Am J Hum Genet 1998; 62: 768-75.
26. Garcia JM, Silva JM, Dominguez G, Silva J, Bonilla F. Heterogeneous cancer clones as an explanation of discordance between plasma DNA and cancer DNA alterations. Genes Chromosomes Cancer 2001; 31: 300-1.
27. Huang ZH, Li LH, Hua D. Quantitative analysis of plasma circulating DNA at diagnosis and during follow-up of breast cancer patients. Cancer Lett 2006; 243: 64-70.
28. Fiegl H, Millinger S, Mueller-Holzner E et al. Circulating cancer-specific DNA: a marker for monitoring efficacy of adjuvant therapy in cancer patients. Cancer Res 2005; 65: 1141-5.
29. Silva JM, Dominguez G, Garcia JM et al. Presence of tumor DNA in plasma of breast cancer patients: clinicopathological correlations. Cancer Res 1999; 59: 3251-6.
30. Theodoropoulos PA, Polioudaki H, Agelaki S et al. Circulating cancer cells with a putative stem cell phenotype in peripheral blood of patients with breast cancer. Cancer Lett 2010; 288: 99-106.
31. Gautschi O, Bigosch C, Huegli B et al. Circulating deoxyribonucleic acid as prognostic marker in non-small-cell lung cancer patients undergoing chemotherapy. J Clin Oncol 2004; 22: 4157-64.
32. Houston SJ, Plunkett TA, Barnes DM, Smith P, Rubens RD, Miles DW. Overexpression of c-erbB2 is an independent marker of resistance to endocrine therapy in advanced breast cancer. Br J Cancer 1999; 79: 1220-6.
33. Dent R, Trudeau M, Pritchard KI et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 2007; 13: 4429-34.